CRISPR THERAPEUTICS AG Operating Cash Flow
CRISPR THERAPEUTICS AG (CRSP) reported Operating Cash Flow of -$192.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$83.50M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$108.90M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$92.55M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$84.63M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for fiscal 2025 was -$345.01M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for fiscal 2024 was -$142.77M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for fiscal 2023 was -$260.38M.
- CRISPR THERAPEUTICS AG net cash provided by (used in) operating activities for fiscal 2022 was -$495.74M, a 191.98% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$83.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$192.40M 10-Q · filed 2026-08-03 | -$284.95M derived: sum of 3 quarters · filed 2026-08-03 | -$369.58M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$108.90M 10-Q · filed 2026-05-04 | -$201.45M derived: sum of 2 quarters · filed 2026-05-04 | -$286.08M derived: sum of 3 quarters · filed 2026-05-04 | -$399.96M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$92.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$177.19M derived: sum of 2 quarters · filed 2026-02-12 | -$291.07M derived: sum of 3 quarters · filed 2026-08-03 | -$345.01M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$84.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$198.51M derived: sum of 2 quarters · filed 2026-08-03 | -$252.46M 10-Q · filed 2025-11-10 | -$302.49M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$113.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$167.83M 10-Q · filed 2026-08-03 | -$217.86M derived: sum of 3 quarters · filed 2026-08-03 | -$324.77M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$53.95M 10-Q · filed 2026-05-04 | -$103.98M derived: sum of 2 quarters · filed 2026-05-04 | -$210.89M derived: sum of 3 quarters · filed 2026-05-04 | -$306.47M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$50.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$156.94M derived: sum of 2 quarters · filed 2026-02-12 | -$252.53M derived: sum of 3 quarters · filed 2026-02-12 | -$142.77M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$106.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$202.50M derived: sum of 2 quarters · filed 2025-11-10 | -$92.74M 10-Q · filed 2025-11-10 | -$188.82M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$95.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $14.17M 10-Q · filed 2025-08-04 | -$81.90M derived: sum of 3 quarters · filed 2026-02-12 | -$121.76M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $109.75M 10-Q · filed 2025-05-06 | $13.68M derived: sum of 2 quarters · filed 2026-02-12 | -$26.18M derived: sum of 3 quarters · filed 2026-02-12 | -$159.42M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$96.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$135.93M derived: sum of 2 quarters · filed 2026-02-12 | -$269.17M derived: sum of 3 quarters · filed 2026-02-12 | -$260.38M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$39.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$173.10M derived: sum of 2 quarters · filed 2024-11-05 | -$164.30M 10-Q · filed 2024-11-05 | -$277.63M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | -$133.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$124.45M 10-Q · filed 2024-08-05 | -$237.77M derived: sum of 3 quarters · filed 2025-02-11 | -$342.99M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $8.80M 10-Q · filed 2024-05-08 | -$104.53M derived: sum of 2 quarters · filed 2025-02-11 | -$209.75M derived: sum of 3 quarters · filed 2025-02-11 | -$351.70M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$113.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$218.55M derived: sum of 2 quarters · filed 2025-02-11 | -$360.50M derived: sum of 3 quarters · filed 2025-02-11 | -$495.74M 10-K · filed 2025-02-11 |
| 2022-09-30 | -$105.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$247.17M derived: sum of 2 quarters · filed 2023-11-06 | -$382.41M 10-Q · filed 2023-11-06 | -$468.45M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$141.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$277.19M 10-Q · filed 2023-08-07 | -$363.23M derived: sum of 3 quarters · filed 2024-02-21 | -$444.56M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$135.24M 10-Q · filed 2022-05-09 | -$221.28M derived: sum of 2 quarters · filed 2024-02-21 | -$302.61M derived: sum of 3 quarters · filed 2024-02-21 | $504.40M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$86.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$167.37M derived: sum of 2 quarters · filed 2024-02-21 | $639.63M derived: sum of 3 quarters · filed 2024-02-21 | $538.97M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$81.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $725.67M derived: sum of 2 quarters · filed 2022-11-01 | $625.01M 10-Q · filed 2022-11-01 | $543.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $807.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $706.34M 10-Q · filed 2022-08-08 | $625.13M derived: sum of 3 quarters · filed 2023-02-21 | $549.43M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$100.66M 10-Q · filed 2022-05-09 | -$181.88M derived: sum of 2 quarters · filed 2023-02-21 | -$257.57M derived: sum of 3 quarters · filed 2023-02-21 | -$286.85M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$81.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$156.91M derived: sum of 2 quarters · filed 2023-02-21 | -$186.19M derived: sum of 3 quarters · filed 2023-02-21 | -$238.37M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$75.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$104.98M derived: sum of 2 quarters · filed 2021-11-03 | -$157.15M 10-Q · filed 2021-11-03 | -$153.78M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$29.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$81.45M 10-Q · filed 2021-07-29 | -$78.08M derived: sum of 3 quarters · filed 2022-02-15 | $55.34M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$52.17M 10-Q · filed 2021-04-27 | -$48.80M derived: sum of 2 quarters · filed 2022-02-15 | $84.62M derived: sum of 3 quarters · filed 2022-02-15 | $48.24M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $136.80M derived: sum of 2 quarters · filed 2022-02-15 | $100.41M derived: sum of 3 quarters · filed 2022-02-15 | $56.68M 10-K · filed 2022-02-15 |
| 2019-09-30 | $133.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $97.04M derived: sum of 2 quarters · filed 2020-10-28 | $53.30M 10-Q · filed 2020-10-28 | $24.93M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | -$36.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | -$80.12M 10-Q · filed 2020-07-27 | -$108.49M derived: sum of 3 quarters · filed 2021-02-16 | -$128.46M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | -$43.74M 10-Q · filed 2020-04-28 | -$72.11M derived: sum of 2 quarters · filed 2021-02-16 | -$92.07M derived: sum of 3 quarters · filed 2021-02-16 | -$117.29M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$28.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | -$48.34M derived: sum of 2 quarters · filed 2021-02-16 | -$73.55M derived: sum of 3 quarters · filed 2021-02-16 | -$96.24M 10-K · filed 2021-02-16 |
| 2018-09-30 | -$19.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | -$45.18M derived: sum of 2 quarters · filed 2019-10-28 | -$67.87M 10-Q · filed 2019-10-28 | -$82.71M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | -$25.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$47.90M 10-Q · filed 2019-07-29 | -$62.74M derived: sum of 3 quarters · filed 2020-02-12 | -$78.61M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | -$22.69M 10-Q · filed 2019-04-29 | -$37.53M derived: sum of 2 quarters · filed 2020-02-12 | -$53.40M derived: sum of 3 quarters · filed 2020-02-12 | |
| 2017-12-31 | -$14.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$30.71M derived: sum of 2 quarters · filed 2020-02-12 | -$70.09M 10-K · filed 2020-02-12 | |
| 2017-09-30 | -$15.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$55.25M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$39.38M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | -$52.86M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |